Levonorgestrel and Ethinyl Estradiol
Brand Names: Vienva Tm, Altavera, Kurvelo, Vienva, Sronyx, Levora
Methodology & AI Transparency ⓘ
Levonorgestrel and Ethinyl Estradiol Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage: Levonorgestrel and ethinyl estradiol tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
- 2 Real-world patient consensus: Zero-PHI community consensus: 93% favorable across 20 logged regimens (Vienva Tm, Altavera).
- 3 Typical cash cost range: Dispensing cost comparison spans $8.73 mail/discount cash up to $34.50 uninsured retail (federal NADAC $0.1509).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Levonorgestrel and Ethinyl Estradiol: nausea (8.5%), headache (8.2%), dizziness (5.6%).
Ask our AI Specialists anything about Levonorgestrel and Ethinyl Estradiol
Levonorgestrel and Ethinyl Estradiol Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage: Levonorgestrel and ethinyl estradiol tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective for pregnancy prevention. The efficacy of these contraceptive methods, except sterilization, the IUD, and implants, depend upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. United States.
CLINICAL PHARMACOLOGY Mode of Action Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation). Pharmacokinetics Absorption No specific investigation of the absolute bioavailability of levonorgestrel and ethinyl estradiol in humans has been conducted.
Pharmacokinetic profiling of Levonorgestrel and Ethinyl Estradiol demonstrates an elimination half-life of Mean elimination half-life of 4 to 17 hours across adult Levonorgestrel and Ethinyl Estradiol dosing with ~100% systemic bioavailability (Levonorgestrel and Ethinyl Estradiol) systemic bioavailability; clearance proceeds via dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of levonorgestrel and ethinyl estradiol, reaching clinical onset within oral tmax achieved within 2 to 5 hours following levonorgestrel and ethinyl estradiol ingestion.
Titration schedules for Levonorgestrel and Ethinyl Estradiol (Kit → 90 ug/1 / 20 ug/1 Tablet → 0.05-30/0.075-40/0.125-30 mg-mcg Pack of Tablets → 0.1-0.02 & 0.01mg Pack of Tablets → 90-20mcg Pack of Tablets) require excluding contraindicated in patients with prior serious allergic response to levonorgestrel and ethinyl estradiol (ndc 63629-2344); severe baseline organ impairment where levonorgestrel and ethinyl estradiol accumulation exceeds safe therapeutic margins; real-world patient logs highlight nausea (8.5% of reports), headache (8.2% of reports), fatigue (5.7% of reports) alongside a 93.00% Worth-It consensus.
Reconcile eGFR-adjusted medications before escalating Levonorgestrel and Ethinyl Estradiol in polypharmacy regimens.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Levonorgestrel and Ethinyl Estradiol dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Levonorgestrel and Ethinyl Estradiol (NDC 63629-2344)
- Severe baseline organ impairment where Levonorgestrel and Ethinyl Estradiol accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (20 Reports)
Levonorgestrel and Ethinyl Estradiol Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Levonorgestrel and Ethinyl Estradiol)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the Both reached C(max) ~1.5 hours later with liraglutide. Journal of clinical pharmacology • 2011-12-15 • Randomized Controlled Trial | N = 21 | 88/100 | PMID 21228406 ↗ |
| New Insights on Two levonorgestrel-releasing intrauterine systems for the treatment of heavy: What a 300-Participant Study Found Donasert ® has equivalent real-world benefits and safety during the first 6 months foralleviation of HMB compared to the reference device, Mirena ®. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception • 2021-12-15 • Phase III Randomized Trial | N = 300 | 87/100 | PMID 34180315 ↗ |
| Can This Approach Help? Inside the Latest Research on Levonorgestrel 52-mg Intrauterine Device real-world benefits and safety After The Sponsor, Medicines360, designed the study and oversaw its conduct, including funding the trial and providing all study product free of charge to participants. Obstetrics and gynecology • 2023-05-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37023451 ↗ |
| Can This Approach Help? Inside the Latest Research on How the body absorbs the medicine and biotransformation of orally administered It is concluded that, compared with an equivalent dose of PE1S, daily repeated oral administration of E2V yields consistently lower peripheral plasma levels of E2 and its principal metabolites. Maturitas • 1990-11-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 2124648 ↗ |
Levonorgestrel and Ethinyl Estradiol Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1509/unit (~$4.53/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $8.73 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $10.04 / mo | View logs ↓ |
Levonorgestrel and Ethinyl Estradiol Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Levonorgestrel and Ethinyl Estradiol RxNorm Concept ID | 722152 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1509 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $8.73 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 93.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Levonorgestrel and Ethinyl Estradiol Patient Community, Cohort Filters & Dosage Logs
Cross-verified Levonorgestrel and Ethinyl Estradiol (progestin) monograph synthesizing RxNorm 722152, openFDA FAERS signals, and $8.73–$34.50 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Levonorgestrel and Ethinyl Estradiol community threads and patient logs by age, biological sex, dosage, and treatment duration.